Sigma Of Australia Names Former CFO As New CEO
This article was originally published in PharmAsia News
Australia's Sigma Pharmaceuticals named Mark Hooper, a former CFO, to serve as its new CEO and managing director, effective in September
You may also be interested in...
Two new projects have begun, one on standardizing the assessment of immune responses in individuals vaccinated in clinical trials, the other to improve understanding of potential immunity in patients who have been infected with SARS-CoV-2.
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
The EU’s upcoming pharma strategy offers an important opportunity for change, according to Medicines for Europe. The off-patent industry body has set out five key issues that should be priorities for the EU Commission.